This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): ARRY-142886, ARRY-886, AZD6244, NSC 748727
Description: ARRY-142886 is a novel, selective, non-ATP-competitive inhibitor of MEK (MAP-erk kinase) 1/2 that has demonstrated nanomolar activity against isolated MEK enzyme and in numerous cancer cell lines. MEK, as part of the ras/raf/MEK/erk pathway, regulates cell proliferation, survival, migration and differentiation. Oral administration of ARRY-142886 has demonstrated tumor suppressive or regressive activity in multiple preclinical models of human cancer, including melanoma, pancreatic, colon, lung and breast cancer models.
Deal Structure: In December 2003, Array BioPharma entered into an out-licensing and collaboration agreement with AstraZeneca. Under the agreement, AstraZeneca acquired exclusive worldwide rights to ARRY-142886 and certain second-generation compounds we develop during the collaboration for oncology indications. Under the agreement, Array received an up-front payment of $10 million and a payment of $4 million upon initiation of Phase I clinical testing for ARRY-142886. The agreement also provides for research funding, potential additional development milestone payments of over $81 million and royalties on product sales.
In June 2009, AstraZeneca and Merck announced a collaboration to research a combination anticancer regimen composed of MK-2206 from Merck and AZD6244 (ARRY-886) from AstraZeneca. Under the terms of the agreement, AstraZeneca and Merck will work together to evaluate co-administration of the compounds. All development costs will be shared jointly.
Partners: Array BioPharma, Inc. Cancer Research UK
Additional information available to subscribers only: